Tags

Type your tag names separated by a space and hit enter

Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
Mult Scler. 2009 Mar; 15(3):316-22.MS

Abstract

BACKGROUND

Matrix metalloproteinases are notable contributors to neuroinflammation and blood-brain barrier disruption in multiple sclerosis (MS).

OBJECTIVE

The goal of this study was to determine the serum levels of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), and their tissue inhibitors (TIMP-1) and (TIMP-2), and to investigate their possible relations to type, disability, and severity of MS.

MATERIALS AND METHODS

Eighty-seven patients with definite MS according to the McDonald criteria and 50 healthy controls were enrolled in the study. Their clinical status was evaluated with the Expanded Disability Status Scale. Serum levels were analyzed by enzyme-linked immunoassay.

RESULTS

A significant elevation in MMP-9 serum levels and in the MMP-9/TIMP-1 ratio was found in the whole MS group (P<0.001), in the relapsing-remitting MS (RRMS) (P<0.001), and secondary-progressive MS (SPMS) (P<0.001) groups when compared with the controls. A significant elevation in MMP-2 serum levels and in the MMP-2/TIMP-2 ratio was observed in the primary progressive (P<0.001) and the SPMS (P<0.002) groups when compared with the RRMS group, and this increase was also associated with the disability (P<0.001) and severity (P<0.05) of the disease.

CONCLUSION

We confirmed that metalloproteinases are useful biological markers in MS, providing information about the clinical type, disability, and severity of the disease.

Authors+Show Affiliations

Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. beneivo@seznam.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19153173

Citation

Benesová, Y, et al. "Matrix Metalloproteinase-9 and Matrix Metalloproteinase-2 as Biomarkers of Various Courses in Multiple Sclerosis." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 15, no. 3, 2009, pp. 316-22.
Benesová Y, Vasku A, Novotná H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler. 2009;15(3):316-22.
Benesová, Y., Vasku, A., Novotná, H., Litzman, J., Stourac, P., Beránek, M., Kadanka, Z., & Bednarík, J. (2009). Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 15(3), 316-22. https://doi.org/10.1177/1352458508099482
Benesová Y, et al. Matrix Metalloproteinase-9 and Matrix Metalloproteinase-2 as Biomarkers of Various Courses in Multiple Sclerosis. Mult Scler. 2009;15(3):316-22. PubMed PMID: 19153173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. AU - Benesová,Y, AU - Vasku,A, AU - Novotná,H, AU - Litzman,J, AU - Stourac,P, AU - Beránek,M, AU - Kadanka,Z, AU - Bednarík,J, Y1 - 2009/01/19/ PY - 2009/1/21/entrez PY - 2009/1/21/pubmed PY - 2009/5/23/medline SP - 316 EP - 22 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 15 IS - 3 N2 - BACKGROUND: Matrix metalloproteinases are notable contributors to neuroinflammation and blood-brain barrier disruption in multiple sclerosis (MS). OBJECTIVE: The goal of this study was to determine the serum levels of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-2 (MMP-2), and their tissue inhibitors (TIMP-1) and (TIMP-2), and to investigate their possible relations to type, disability, and severity of MS. MATERIALS AND METHODS: Eighty-seven patients with definite MS according to the McDonald criteria and 50 healthy controls were enrolled in the study. Their clinical status was evaluated with the Expanded Disability Status Scale. Serum levels were analyzed by enzyme-linked immunoassay. RESULTS: A significant elevation in MMP-9 serum levels and in the MMP-9/TIMP-1 ratio was found in the whole MS group (P<0.001), in the relapsing-remitting MS (RRMS) (P<0.001), and secondary-progressive MS (SPMS) (P<0.001) groups when compared with the controls. A significant elevation in MMP-2 serum levels and in the MMP-2/TIMP-2 ratio was observed in the primary progressive (P<0.001) and the SPMS (P<0.002) groups when compared with the RRMS group, and this increase was also associated with the disability (P<0.001) and severity (P<0.05) of the disease. CONCLUSION: We confirmed that metalloproteinases are useful biological markers in MS, providing information about the clinical type, disability, and severity of the disease. SN - 1352-4585 UR - https://www.unboundmedicine.com/medline/citation/19153173/Matrix_metalloproteinase_9_and_matrix_metalloproteinase_2_as_biomarkers_of_various_courses_in_multiple_sclerosis_ L2 - https://journals.sagepub.com/doi/10.1177/1352458508099482?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -